Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID D DEATKINE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1336255850
CMS profile
196335
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,821.56

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,821.56 108

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID D DEATKINE

NPI 1336255850 · CMS profile ID 196335

Allopathic & Osteopathic Physicians / Internal Medicine

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336255850?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID D DEATKINE, NPI 1336255850, CMS profile ID 196335. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336255850?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID D DEATKINE, NPI 1336255850, CMS profile ID 196335. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336255850?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID D DEATKINE, NPI 1336255850, CMS profile ID 196335, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1336255850?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $1,821.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $13.3107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819061643 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.3607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763552968 CMS
AbbVie Inc. $11.1107/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339985 CMS
MannKind Corporation $13.0606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053317 CMS
AbbVie Inc. $2.0806/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339983 CMS
Amarin Pharma Inc. $12.3006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815269191 CMS
TherapeuticsMD, Inc. $22.9406/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844903801 CMS
Lilly USA, LLC $13.9506/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819049411 CMS
IBSA Pharma Inc. $11.1506/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792503887 CMS
Esperion Therapeutics, Inc. $17.1806/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838276661 CMS
AbbVie Inc. $10.9906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339981 CMS
Lilly USA, LLC $14.6006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819049419 CMS
Novo Nordisk Inc $11.3705/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810920311 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1005/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763552970 CMS
AbbVie Inc. $9.5005/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339979 CMS
MannKind Corporation $20.5605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053309 CMS
MannKind Corporation $125.0005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053313 CMS
Amgen Inc. $11.6605/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825251527 CMS
Nestle HealthCare Nutrition Inc. $20.4905/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820888111 CMS
MannKind Corporation $4.5805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053305 CMS
SANOFI-AVENTIS U.S. LLC $16.8404/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843428909 CMS
Esperion Therapeutics, Inc. $7.6704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838276657 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1804/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763552972 CMS
AbbVie Inc. $12.1004/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339977 CMS
TherapeuticsMD, Inc. $17.2804/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844903797 CMS
Lilly USA, LLC $10.1904/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819060429 CMS
Xeris Pharmaceuticals, Inc. $16.2804/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837418259 CMS
MannKind Corporation $13.8404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053301 CMS
Merck Sharp & Dohme Corporation $14.3004/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848464903 CMS
AbbVie Inc. $12.4204/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339975 CMS
Corcept Therapeutics $19.2504/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837523003 CMS
AbbVie Inc. $15.3004/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339973 CMS
AbbVie Inc. $13.0703/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339971 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.0403/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763552974 CMS
DEXCOM, INC. $21.2403/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845274551 CMS
Lilly USA, LLC $14.8503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819060433 CMS
AbbVie Inc. $2.2303/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339969 CMS
AbbVie Inc. $4.0303/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339967 CMS
MannKind Corporation $17.1403/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053295 CMS
Novo Nordisk Inc $12.1403/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810756981 CMS
Eisai Inc. $12.3902/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817857415 CMS
MannKind Corporation $20.4902/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053287 CMS
MannKind Corporation $20.4902/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053291 CMS
AbbVie Inc. $11.7702/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339965 CMS
AbbVie Inc. $13.5802/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794339963 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.2602/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819909067 CMS
Amgen Inc. $12.5702/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825251523 CMS
Esperion Therapeutics, Inc. $105.8002/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838276651 CMS
Esperion Therapeutics, Inc. $14.7802/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838276647 CMS
Corcept Therapeutics $19.4302/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837523001 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,010.19 47
PY2020 $1,180.19 62
PY2021 $1,821.56 108
PY2022 $2,513.03 60
PY2023 $2,439.73 36
PY2024 $900.97 43
PY2025 $860.10 39

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,888,757.25 411
PY2024 Recipient $39,378.54 3
PY2024 Principal investigator $1,020,648.31 238
PY2023 Principal investigator $1,592,173.61 70
PY2022 Principal investigator $1,240,423.58 129
PY2021 Principal investigator $611,526.05 52
PY2020 Principal investigator $327,565.44 35
PY2019 Recipient $1,689.64 1
PY2019 Principal investigator $313,089.43 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

411 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,587.00 12/31/2025 Non-covered Recipient Entity
FLOURISH RESEARCH
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533865
Principal investigator 1 ABBVIE INC. $300.00 12/31/2025 Non-covered Recipient Entity
FLOURISH RESEARCH
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202533867
Principal investigator 1 Ionis Pharmaceuticals, Inc. $150.00 12/30/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246792146
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,300.00 12/30/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246792151
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,500.00 12/30/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246792155
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,500.00 12/30/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246792159
Principal investigator 1 Ipsen Innovation $971.28 12/24/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295261
Principal investigator 1 Ipsen Innovation $2,078.88 12/24/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295269
Principal investigator 1 Ipsen Innovation $1,915.58 12/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295265
Principal investigator 1 Ipsen Innovation $413.30 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295257
Principal investigator 1 Ipsen Innovation $21.30 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295259
Principal investigator 1 Ipsen Innovation $418.90 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295263
Principal investigator 1 Ipsen Innovation $489.90 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295267
Principal investigator 1 Ipsen Innovation $92.30 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295271
Principal investigator 1 Ipsen Innovation $21.30 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295275
Principal investigator 1 Ipsen Innovation $434.60 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295277
Principal investigator 1 Ipsen Innovation $21.30 12/19/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295279
Principal investigator 1 Eli Lilly and Company $471.45 12/17/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187880901
Principal investigator 1 Ipsen Innovation $71.00 12/12/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295255
Principal investigator 1 Ipsen Innovation $21.30 12/12/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295273
Principal investigator 1 Eli Lilly and Company $525.01 12/10/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187883710
Principal investigator 1 ABBVIE INC. $5,182.80 12/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529362
Principal investigator 1 Ipsen Innovation $150.00 12/03/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295281
Principal investigator 1 Ipsen Innovation $167.56 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295233
Principal investigator 1 Ipsen Innovation $284.00 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295235
Principal investigator 1 Ipsen Innovation $250.00 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295239
Principal investigator 1 Ipsen Innovation $800.00 11/27/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295241
Principal investigator 1 Ipsen Innovation $42.60 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295243
Principal investigator 1 Ipsen Innovation $163.30 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295247
Principal investigator 1 Ipsen Innovation $400.00 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295249
Principal investigator 1 Ipsen Innovation $800.00 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295251
Principal investigator 1 Ipsen Innovation $163.30 11/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295253
Principal investigator 1 ModernaTX, Inc. $296.40 11/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004909
Principal investigator 1 ABBVIE INC. $243.60 11/26/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202525558
Principal investigator 1 Ipsen Innovation $1,158.72 11/24/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295237
Principal investigator 1 Ipsen Innovation $971.28 11/24/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295245
Principal investigator 1 ABBVIE INC. $800.00 11/20/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202525090
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187876631
Principal investigator 1 ABBVIE INC. $51,842.00 11/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521597
Principal investigator 1 ABBVIE INC. $316.00 11/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521599
Principal investigator 1 ABBVIE INC. $730.80 11/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521601
Principal investigator 1 ABBVIE INC. $974.40 11/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521603
Principal investigator 1 ABBVIE INC. $189.60 11/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522341
Principal investigator 1 ABBVIE INC. $252.80 11/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522343
Principal investigator 1 PFIZER INC. $6,026.29 11/01/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228713942
Principal investigator 1 ABBVIE INC. $9,100.00 10/30/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202519735
Principal investigator 1 Ipsen Innovation $21.30 10/30/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296721
Principal investigator 1 Ipsen Innovation $71.00 10/30/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296733
Principal investigator 1 ABBVIE INC. $1,500.00 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518717
Principal investigator 1 ABBVIE INC. $220.76 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518765
Principal investigator 1 ABBVIE INC. $600.40 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518767
Principal investigator 1 ABBVIE INC. $348.60 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518769
Principal investigator 1 ABBVIE INC. $974.40 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518771
Principal investigator 1 ABBVIE INC. $1,218.00 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518773
Principal investigator 1 ABBVIE INC. $330.00 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518775
Principal investigator 1 ABBVIE INC. $487.20 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518777
Principal investigator 1 ABBVIE INC. $500.00 10/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518801
Principal investigator 1 Eli Lilly and Company $263.35 10/28/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187881060
Principal investigator 1 Ipsen Innovation $971.28 10/27/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296715
Principal investigator 1 Ipsen Innovation $971.28 10/27/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296717
Principal investigator 1 Ipsen Innovation $2,563.10 10/27/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296723
Principal investigator 1 Ipsen Innovation $1,894.28 10/27/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296725
Principal investigator 1 Ipsen Innovation $3,020.34 10/27/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296731
Principal investigator 1 Ipsen Innovation $213.00 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296705
Principal investigator 1 Ipsen Innovation $21.30 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296707
Principal investigator 1 Ipsen Innovation $21.30 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296709
Principal investigator 1 Ipsen Innovation $142.00 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296711
Principal investigator 1 Ipsen Innovation $392.00 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296713
Principal investigator 1 Ipsen Innovation $21.30 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296719
Principal investigator 1 Ipsen Innovation $163.30 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296727
Principal investigator 1 Ipsen Innovation $450.00 10/10/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296729
Principal investigator 1 ABBVIE INC. $46,699.10 10/09/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515693
Principal investigator 1 PFIZER INC. $6,822.92 10/08/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228741219
Principal investigator 1 ABBVIE INC. $1,210.00 10/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513401
Principal investigator 1 ABBVIE INC. $410.00 10/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513433
Principal investigator 1 ABBVIE INC. $730.80 10/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513441
Principal investigator 1 Ipsen Innovation $971.28 09/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296663
Principal investigator 1 Ipsen Innovation $1,894.28 09/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296665
Principal investigator 1 Ipsen Innovation $971.28 09/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296683
Principal investigator 1 Ipsen Innovation $1,894.28 09/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296689
Principal investigator 1 Ipsen Innovation $971.28 09/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296691
Principal investigator 1 Ipsen Innovation $971.28 09/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296701
Principal investigator 1 Ipsen Innovation $142.00 09/26/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296661
Principal investigator 1 Ipsen Innovation $213.00 09/26/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296667
Principal investigator 1 Ipsen Innovation $21.30 09/26/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296671
Principal investigator 1 Ipsen Innovation $113.60 09/26/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296693
Principal investigator 1 Ipsen Innovation $92.30 09/26/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296697
Principal investigator 1 Ipsen Innovation $92.30 09/26/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296699
Principal investigator 1 Ipsen Innovation $21.30 09/26/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296703
Principal investigator 1 Ipsen Innovation $400.00 09/25/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296685
Principal investigator 1 PFIZER INC. $732.34 09/24/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228768567
Principal investigator 1 Ipsen Innovation $21.30 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296669
Principal investigator 1 Ipsen Innovation $142.00 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296673
Principal investigator 1 Ipsen Innovation $150.00 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296675
Principal investigator 1 Ipsen Innovation $142.00 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296677
Principal investigator 1 Ipsen Innovation $71.00 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296679
Principal investigator 1 Ipsen Innovation $600.00 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296681
Principal investigator 1 Ipsen Innovation $142.00 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296687
Principal investigator 1 Ipsen Innovation $142.00 09/17/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296695
Principal investigator 1 ABBVIE INC. $974.40 09/04/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508704
Principal investigator 1 ABBVIE INC. $43,680.70 09/04/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509696
Principal investigator 1 ABBVIE INC. $195.92 09/04/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509698
Principal investigator 1 ABBVIE INC. $559.32 09/04/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509700
Principal investigator 1 ABBVIE INC. $500.00 09/04/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509702
Principal investigator 1 ABBVIE INC. $215.52 09/04/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509704
Principal investigator 1 PFIZER INC. $6,409.62 09/03/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228771477
Principal investigator 1 Ipsen Innovation $2,448.08 08/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295187
Principal investigator 1 Ipsen Innovation $2,078.88 08/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295199
Principal investigator 1 Ipsen Innovation $1,894.28 08/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295203
Principal investigator 1 Ipsen Innovation $971.28 08/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295205
Principal investigator 1 Ipsen Innovation $96.56 08/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295209
Principal investigator 1 Ipsen Innovation $1,894.28 08/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295213
Principal investigator 1 Ipsen Innovation $96.56 08/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295215
Principal investigator 1 Ipsen Innovation $971.28 08/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295217
Principal investigator 1 Ipsen Innovation $384.30 08/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295219
Principal investigator 1 Ipsen Innovation $2,078.88 08/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295225
Principal investigator 1 ModernaTX, Inc. $237.12 08/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004957
Principal investigator 1 Ipsen Innovation $300.00 08/25/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295173
Principal investigator 1 Ipsen Innovation $71.00 08/22/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295195
Principal investigator 1 Ipsen Innovation $71.00 08/22/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295211
Principal investigator 1 Ipsen Innovation $21.30 08/22/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295229
Principal investigator 1 Ipsen Innovation $21.30 08/22/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295231
Principal investigator 1 Ionis Pharmaceuticals, Inc. $150.00 08/18/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246786638
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,300.00 08/18/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246786643
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,500.00 08/18/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246786647
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,500.00 08/18/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INCS
IS354CS9 No dispute reported 06/30/2026 1246786652
Principal investigator 1 Ipsen Innovation $36.43 08/15/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295175
Principal investigator 1 Ipsen Innovation $250.00 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295177
Principal investigator 1 Ipsen Innovation $21.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295179
Principal investigator 1 Ipsen Innovation $92.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295181
Principal investigator 1 Ipsen Innovation $163.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295183
Principal investigator 1 Ipsen Innovation $71.00 08/13/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295185
Principal investigator 1 Ipsen Innovation $92.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295189
Principal investigator 1 Ipsen Innovation $92.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295191
Principal investigator 1 Ipsen Innovation $21.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295193
Principal investigator 1 Ipsen Innovation $65.00 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295197
Principal investigator 1 Ipsen Innovation $92.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295201
Principal investigator 1 Ipsen Innovation $163.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295207
Principal investigator 1 Ipsen Innovation $92.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295221
Principal investigator 1 Ipsen Innovation $71.00 08/13/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295223
Principal investigator 1 Ipsen Innovation $92.30 08/13/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295227
Principal investigator 1 ABBVIE INC. $211.12 08/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503745
Principal investigator 1 AstraZeneca Pharmaceuticals LP $41,340.00 08/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185539421
Principal investigator 1 ABBVIE INC. $9,080.00 08/06/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202502514
Principal investigator 1 ABBVIE INC. $24,098.20 08/06/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502516
Principal investigator 1 ABBVIE INC. $84.09 08/05/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202501324
Principal investigator 1 PFIZER INC. $12,768.77 08/05/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228720373
Principal investigator 1 Ipsen Innovation $21.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295113
Principal investigator 1 Ipsen Innovation $142.00 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295115
Principal investigator 1 Ipsen Innovation $71.00 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295117
Principal investigator 1 Ipsen Innovation $213.00 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295119
Principal investigator 1 Ipsen Innovation $1,894.28 07/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295121
Principal investigator 1 Ipsen Innovation $92.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295123
Principal investigator 1 Ipsen Innovation $255.60 07/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295125
Principal investigator 1 Ipsen Innovation $971.28 07/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295127
Principal investigator 1 Ipsen Innovation $21.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295129
Principal investigator 1 Ipsen Innovation $971.28 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295133
Principal investigator 1 Ipsen Innovation $300.00 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295139
Principal investigator 1 Ipsen Innovation $21.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295141
Principal investigator 1 Ipsen Innovation $971.28 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295143
Principal investigator 1 Ipsen Innovation $213.00 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295145
Principal investigator 1 Ipsen Innovation $21.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295147
Principal investigator 1 Ipsen Innovation $971.28 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295149
Principal investigator 1 Ipsen Innovation $213.00 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295151
Principal investigator 1 Ipsen Innovation $21.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295153
Principal investigator 1 Ipsen Innovation $21.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295161
Principal investigator 1 Ipsen Innovation $92.30 07/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295165
Principal investigator 1 Ipsen Innovation $150.00 07/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295169
Principal investigator 1 Ipsen Innovation $71.00 07/25/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295131
Principal investigator 1 Ipsen Innovation $150.00 07/25/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295137
Principal investigator 1 Ipsen Innovation $21.30 07/25/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295155
Principal investigator 1 Ipsen Innovation $42.60 07/25/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295159
Principal investigator 1 Ipsen Innovation $142.00 07/25/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295163
Principal investigator 1 Ipsen Innovation $1,000.00 07/25/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295167
Principal investigator 1 Ipsen Innovation $250.00 07/25/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295171
Principal investigator 1 Ipsen Innovation $250.00 07/23/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295157
Principal investigator 1 Ipsen Innovation $300.00 07/21/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295109
Principal investigator 1 Ipsen Innovation $300.00 07/21/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295111
Principal investigator 1 Ipsen Innovation $36.43 07/18/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295107
Principal investigator 1 PFIZER INC. $15,419.25 07/17/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228785060
Principal investigator 1 AstraZeneca UK Limited $96,883.62 07/16/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity No dispute reported 06/30/2026 1185539419
Principal investigator 1 Ipsen Innovation $36.43 07/16/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295105
Principal investigator 1 Ipsen Innovation $1,000.00 07/14/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295135
Principal investigator 1 ABBVIE INC. $500.00 07/08/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202497032
Principal investigator 1 ABBVIE INC. $221.20 07/08/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202497034
Principal investigator 1 ABBVIE INC. $32,576.60 07/02/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494125
Principal investigator 1 GlaxoSmithKline, LLC. $1,410.00 07/01/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192130501
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 07/01/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192130506
Principal investigator 1 Ipsen Innovation $71.00 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295079
Principal investigator 1 Ipsen Innovation $1,894.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295081
Principal investigator 1 Ipsen Innovation $21.30 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295083
Principal investigator 1 Ipsen Innovation $2,426.78 06/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295085
Principal investigator 1 Ipsen Innovation $2,078.88 06/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295087
Principal investigator 1 Ipsen Innovation $971.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295089
Principal investigator 1 Ipsen Innovation $971.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295091
Principal investigator 1 Ipsen Innovation $971.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295093
Principal investigator 1 Ipsen Innovation $971.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295095
Principal investigator 1 Ipsen Innovation $971.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295097
Principal investigator 1 Ipsen Innovation $1,894.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295099
Principal investigator 1 Ipsen Innovation $2,057.58 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295101
Principal investigator 1 Ipsen Innovation $971.28 06/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295103
Principal investigator 1 ModernaTX, Inc. $9,210.52 06/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004923
Principal investigator 1 ABBVIE INC. $1,917.00 06/26/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202493221
Principal investigator 1 ABBVIE INC. $243.60 06/26/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202493223
Principal investigator 1 PFIZER INC. $55,849.71 06/26/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228793624
Principal investigator 1 ABBVIE INC. $800.00 06/25/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492855
Principal investigator 1 ABBVIE INC. $480.00 06/25/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492857
Principal investigator 1 Ionis Pharmaceuticals, Inc. $100.00 06/19/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
IS354CS6 No dispute reported 06/30/2026 1246784384
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,542.00 06/18/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185539425
Principal investigator 1 Ipsen Innovation $150.00 06/12/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295073
Principal investigator 1 Ipsen Innovation $150.00 06/12/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295075
Principal investigator 1 Ipsen Innovation $180.00 06/12/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295077
Principal investigator 1 ABBVIE INC. $64,982.40 06/03/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488531
Principal investigator 1 PFIZER INC. $14,000.00 05/30/2025 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228773942
Principal investigator 1 Ipsen Innovation $142.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296561
Principal investigator 1 Ipsen Innovation $92.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296563
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296565
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296569
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296571
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296573
Principal investigator 1 Ipsen Innovation $15.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296575
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296577
Principal investigator 1 Ipsen Innovation $3,195.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296579
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296587
Principal investigator 1 Ipsen Innovation $142.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296589
Principal investigator 1 Ipsen Innovation $42.60 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296591
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296593
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296597
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296599
Principal investigator 1 Ipsen Innovation $213.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296603
Principal investigator 1 Ipsen Innovation $234.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296607
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296609
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296613
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296615
Principal investigator 1 Ipsen Innovation $50.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296617
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296625
Principal investigator 1 Ipsen Innovation $92.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296627
Principal investigator 1 Ipsen Innovation $213.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296629
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296633
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296635
Principal investigator 1 Ipsen Innovation $234.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296637
Principal investigator 1 Ipsen Innovation $255.60 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296641
Principal investigator 1 Ipsen Innovation $400.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296645
Principal investigator 1 Ipsen Innovation $71.00 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296647
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296649
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296651
Principal investigator 1 Ipsen Innovation $21.30 05/29/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296657
Principal investigator 1 Ipsen Innovation $2,057.58 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296559
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296567
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296581
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296583
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296585
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296595
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296601
Principal investigator 1 Ipsen Innovation $2,426.78 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296605
Principal investigator 1 Ipsen Innovation $2,057.58 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296611
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296619
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296621
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296623
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296631
Principal investigator 1 Ipsen Innovation $1,872.98 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296639
Principal investigator 1 Ipsen Innovation $1,872.98 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296655
Principal investigator 1 Ipsen Innovation $971.28 05/28/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296659
Principal investigator 1 ModernaTX, Inc. $11,381.76 05/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004925
Principal investigator 1 ModernaTX, Inc. $48,983.22 05/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004935
Principal investigator 1 ModernaTX, Inc. $1,461.00 05/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004947
Principal investigator 1 PFIZER INC. $2,586.12 05/27/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228754746
Principal investigator 1 PFIZER INC. $2,586.12 05/27/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228760511
Principal investigator 1 ABBVIE INC. $1,230.00 05/20/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202485449
Principal investigator 1 ABBVIE INC. $487.20 05/20/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202485451
Principal investigator 1 Ipsen Innovation $400.00 05/19/2025 Non-covered Recipient Entity
Central Alabama Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296643
Principal investigator 1 ABBVIE INC. $259.12 05/15/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484943
Principal investigator 1 ABBVIE INC. $1,500.00 05/15/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484945
Principal investigator 1 ModernaTX, Inc. $500.00 05/15/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004937
Principal investigator 1 AstraZeneca UK Limited $151,694.00 05/09/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185539427
Principal investigator 1 Ipsen Innovation $400.00 05/09/2025 Non-covered Recipient Entity
Central Alabama Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296653
Principal investigator 1 ABBVIE INC. $2,730.00 05/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482347
Principal investigator 1 ABBVIE INC. $18,828.60 05/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482399
Principal investigator 1 ModernaTX, Inc. $592.80 05/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004941
Principal investigator 1 Ipsen Innovation $971.28 04/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294963
Principal investigator 1 Ipsen Innovation $971.28 04/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294969
Principal investigator 1 Ipsen Innovation $971.28 04/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295021
Principal investigator 1 Ipsen Innovation $971.28 04/30/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295059
Principal investigator 1 Ipsen Innovation $971.28 04/30/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295061
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294981
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294985
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294987
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294989
Principal investigator 1 Ipsen Innovation $600.00 04/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294991
Principal investigator 1 Ipsen Innovation $180.00 04/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294993
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294999
Principal investigator 1 Ipsen Innovation $2,977.74 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295003
Principal investigator 1 Ipsen Innovation $1,137.42 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295023
Principal investigator 1 Ipsen Innovation $1,872.98 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295027
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295033
Principal investigator 1 Ipsen Innovation $2,426.78 04/28/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295035
Principal investigator 1 Ipsen Innovation $2,057.58 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295037
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295043
Principal investigator 1 Ipsen Innovation $2,541.80 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295047
Principal investigator 1 Ipsen Innovation $2,426.78 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295065
Principal investigator 1 Ipsen Innovation $971.28 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295067
Principal investigator 1 Ipsen Innovation $2,057.58 04/28/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295071
Principal investigator 1 ModernaTX, Inc. $23,376.00 04/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004933
Principal investigator 1 ModernaTX, Inc. $10,885.16 04/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004949
Principal investigator 1 ModernaTX, Inc. $14,839.76 04/28/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004955
Principal investigator 1 Ipsen Innovation $92.30 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294965
Principal investigator 1 Ipsen Innovation $2,977.74 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294967
Principal investigator 1 Ipsen Innovation $75.26 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294971
Principal investigator 1 Ipsen Innovation $92.30 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294979
Principal investigator 1 Ipsen Innovation $92.30 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294983
Principal investigator 1 Ipsen Innovation $92.30 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295005
Principal investigator 1 Ipsen Innovation $142.00 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295007
Principal investigator 1 Ipsen Innovation $880.74 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295013
Principal investigator 1 Ipsen Innovation $75.26 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295015
Principal investigator 1 Ipsen Innovation $142.00 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295019
Principal investigator 1 Ipsen Innovation $150.00 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295031
Principal investigator 1 Ipsen Innovation $92.30 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295039
Principal investigator 1 Ipsen Innovation $92.30 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295045
Principal investigator 1 Ipsen Innovation $92.30 04/23/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295053
Principal investigator 1 Ipsen Innovation $600.00 04/21/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294995
Principal investigator 1 Ipsen Innovation $270.00 04/21/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294997
Principal investigator 1 PFIZER INC. $2,155.10 04/21/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228724754
Principal investigator 1 PFIZER INC. $2,155.10 04/21/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228769396
Principal investigator 1 ABBVIE INC. $259.00 04/16/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202476954
Principal investigator 1 ABBVIE INC. $243.60 04/16/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202476958
Principal investigator 1 PFIZER INC. $426.60 04/11/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228713946
Principal investigator 1 Ipsen Innovation $21.30 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294973
Principal investigator 1 Ipsen Innovation $142.00 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294975
Principal investigator 1 Ipsen Innovation $21.30 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294977
Principal investigator 1 Ipsen Innovation $21.30 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295001
Principal investigator 1 Ipsen Innovation $71.00 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295009
Principal investigator 1 Ipsen Innovation $150.00 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295011
Principal investigator 1 Ipsen Innovation $30.00 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295017
Principal investigator 1 Ipsen Innovation $213.00 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295025
Principal investigator 1 Ipsen Innovation $21.30 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295029
Principal investigator 1 Ipsen Innovation $213.00 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295041
Principal investigator 1 Ipsen Innovation $490.50 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295049
Principal investigator 1 Ipsen Innovation $21.30 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295051
Principal investigator 1 Ipsen Innovation $21.30 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295057
Principal investigator 1 Ipsen Innovation $42.60 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295063
Principal investigator 1 Ipsen Innovation $213.00 04/09/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295069
Principal investigator 1 Ipsen Innovation $1,000.69 04/07/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184295055
Principal investigator 1 ABBVIE INC. $17,071.60 04/03/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471138
Principal investigator 1 ABBVIE INC. $487.20 04/01/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202467837
Principal investigator 1 GlaxoSmithKline, LLC. $2,299.48 04/01/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192126977
Principal investigator 1 PFIZER INC. $5,603.26 04/01/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228743595
Principal investigator 1 PFIZER INC. $5,603.26 04/01/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228770853
Principal investigator 1 ABBVIE INC. $730.80 03/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202466605
Principal investigator 1 ABBVIE INC. $243.60 03/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202466610
Principal investigator 1 Ipsen Innovation $450.00 03/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294959
Principal investigator 1 ABBVIE INC. $158.00 03/26/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202466134
Principal investigator 1 ABBVIE INC. $500.00 03/26/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202466160
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 03/26/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192126973
Principal investigator 1 ModernaTX, Inc. $7,425.60 03/24/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004913
Principal investigator 1 ModernaTX, Inc. $80.60 03/24/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004921
Principal investigator 1 ModernaTX, Inc. $5,023.92 03/24/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004929
Principal investigator 1 ModernaTX, Inc. $13,990.08 03/24/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004939
Principal investigator 1 ModernaTX, Inc. $18,993.00 03/24/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004943
Principal investigator 1 Ipsen Innovation $36.43 03/18/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294957
Principal investigator 1 Ipsen Innovation $165.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294911
Principal investigator 1 Ipsen Innovation $121.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294913
Principal investigator 1 Ipsen Innovation $142.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294915
Principal investigator 1 Ipsen Innovation $71.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294917
Principal investigator 1 Ipsen Innovation $21.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294919
Principal investigator 1 Ipsen Innovation $71.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294921
Principal investigator 1 Ipsen Innovation $400.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294923
Principal investigator 1 Ipsen Innovation $36.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294925
Principal investigator 1 Ipsen Innovation $255.60 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294927
Principal investigator 1 Ipsen Innovation $71.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294929
Principal investigator 1 Ipsen Innovation $21.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294931
Principal investigator 1 Ipsen Innovation $263.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294933
Principal investigator 1 Ipsen Innovation $71.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294935
Principal investigator 1 Ipsen Innovation $21.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294937
Principal investigator 1 Ipsen Innovation $234.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294939
Principal investigator 1 Ipsen Innovation $450.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294941
Principal investigator 1 Ipsen Innovation $234.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294943
Principal investigator 1 Ipsen Innovation $92.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294945
Principal investigator 1 Ipsen Innovation $165.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294947
Principal investigator 1 Ipsen Innovation $450.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294949
Principal investigator 1 Ipsen Innovation $15.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294951
Principal investigator 1 Ipsen Innovation $142.00 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294953
Principal investigator 1 Ipsen Innovation $21.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294955
Principal investigator 1 Ipsen Innovation $92.30 03/17/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294961
Principal investigator 1 PFIZER INC. $1,279.80 03/17/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228713944
Principal investigator 1 PFIZER INC. $677.05 03/17/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228774133
Principal investigator 1 PFIZER INC. $793.65 03/17/2025 Non-covered Recipient Entity
Central Research Associates
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228774603
Principal investigator 1 ABBVIE INC. $35,119.00 03/07/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459477
Principal investigator 1 ModernaTX, Inc. $32,142.00 02/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004911
Principal investigator 1 ModernaTX, Inc. $15,432.56 02/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004927
Principal investigator 1 ModernaTX, Inc. $1,041.10 02/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004945
Principal investigator 1 ModernaTX, Inc. $27,631.56 02/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004951
Principal investigator 1 ModernaTX, Inc. $218.40 02/19/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004953
Principal investigator 1 GlaxoSmithKline, LLC. $126.60 02/12/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192126967
Principal investigator 1 ABBVIE INC. $34,101.90 02/06/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202446807
Principal investigator 1 Eli Lilly and Company $13,185.11 01/31/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187877695
Principal investigator 1 Ipsen Innovation $400.00 01/29/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294903
Principal investigator 1 Eli Lilly and Company $1,403,720.14 01/28/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187881058
Principal investigator 1 Ipsen Innovation $971.28 01/27/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294897
Principal investigator 1 ModernaTX, Inc. $29,220.00 01/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004915
Principal investigator 1 ModernaTX, Inc. $15,511.60 01/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004917
Principal investigator 1 ModernaTX, Inc. $16,657.60 01/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004919
Principal investigator 1 ModernaTX, Inc. $8,373.20 01/27/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004931
Principal investigator 1 AstraZeneca UK Limited $22,755.00 01/22/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185539423
Principal investigator 1 Ipsen Innovation $115.00 01/20/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294901
Principal investigator 1 Ipsen Innovation $3,914.31 01/20/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294907
Principal investigator 1 Ipsen Innovation $195.00 01/16/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294895
Principal investigator 1 Ipsen Innovation $15.00 01/16/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294899
Principal investigator 1 Ipsen Innovation $113.60 01/16/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294905
Principal investigator 1 Ipsen Innovation $21.30 01/16/2025 Non-covered Recipient Entity
Flourish Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294909
Principal investigator 1 Eli Lilly and Company $69,009.20 01/07/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187881188
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,376.00 01/03/2025 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185539429